Premium
Pro‐ and antiangiogenic therapies: current status and clinical implications
Author(s) -
Rust Ruslan,
Gantner Christina,
Schwab Martin E.
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201800640rr
Subject(s) - medicine , angiogenesis , disease , blood vessel , stroke (engine) , intensive care medicine , bioinformatics , neuroscience , pathology , biology , mechanical engineering , engineering
Blood vessels nurture every part of the human body. Consequently, abnormalities in the vasculature are closely associated with a variety of diseases, including cerebral stroke, heart disease, retinopathy, and cancer. Pro‐ or antiangiogenic therapies can influence these diseases by regulating the growth of new blood vessels from a pre‐existing vascular network or dampening excessive blood growth. However, clinical translation of these approaches is slow and challenging. In this review, we discuss recent preclinical approaches to regulate angiogenesis and their potential and risks in a clinical setting.—Rust, R., Gantner, C., Schwab, M. E. Pro‐ and antiangiogenic therapies: current status and clinical implications. FASEB J. 33, 34–48 (2019). www.fasebj.org